Literature DB >> 9667966

Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.

D E Bierer1, L G Dubenko, P Zhang, Q Lu, P A Imbach, A W Garofalo, P W Phuan, D M Fort, J Litvak, R E Gerber, B Sloan, J Luo, R Cooper, G M Reaven.   

Abstract

Cryptolepine (1) is a rare example of a natural product whose synthesis was reported prior to its isolation from nature. In the previous paper we reported the discovery of cryptolepine's antihyperglycemic properties. As part of a medicinal chemistry program designed to optimize natural product lead structures originating from our ethnobotanical and ethnomedical field research, a series of substituted and heterosubstituted cryptolepine analogues was synthesized. Antihyperglycemic activity was measured in vitro and in an NIDDM mouse model to generate the first structure-bioactivity study about the cryptolepine nucleus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667966     DOI: 10.1021/jm970735n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.

Authors:  Comfort A Boateng; Suresh V K Eyunni; Xue Y Zhu; Jagan R Etukala; Barbara A Bricker; M K Ashfaq; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2010-11-10       Impact factor: 3.641

2.  Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents.

Authors:  Xue Y Zhu; Leroy G Mardenborough; Shouming Li; Abdul Khan; Wang Zhang; Pincheng Fan; Melissa Jacob; Shabana Khan; Larry Walker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2006-11-01       Impact factor: 3.641

3.  Novel synthesis of a series of spiro 1,3-indanedione-fused dihydropyridines through the condensation of a tetrone with N-aryl/alkylenamines in presence of solid support silica sulfuric acid.

Authors:  Ashis Kundu; Animesh Pramanik
Journal:  Mol Divers       Date:  2015-03-24       Impact factor: 2.943

4.  Recent Advances in the Chemistry and Pharmacology of Cryptolepine.

Authors:  Steven D Shnyder; Colin W Wright
Journal:  Prog Chem Org Nat Prod       Date:  2021

5.  Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter.

Authors:  Peda V L Boddupally; Seongmin Hahn; Cristina Beman; Biswanath De; Tracy A Brooks; Vijay Gokhale; Laurence H Hurley
Journal:  J Med Chem       Date:  2012-06-25       Impact factor: 7.446

6.  Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  Daniel Laryea; Anders Isaksson; Colin W Wright; Rolf Larsson; Peter Nygren
Journal:  Invest New Drugs       Date:  2008-10-14       Impact factor: 3.850

Review 7.  Indolo[3,2-b]quinolines: synthesis, biological evaluation and structure activity-relationships.

Authors:  Eyunni V K Suresh Kumar; Jagan R Etukala; Seth Y Ablordeppey
Journal:  Mini Rev Med Chem       Date:  2008-06       Impact factor: 3.862

8.  Antifertility activity of Cryptolepis sanguinolenta leaf ethanolic extract in male rats.

Authors:  Ayodeji F Ajayi; Roland E Akhigbe
Journal:  J Hum Reprod Sci       Date:  2012-01

9.  3-[4-(10H-Indolo[3,2-b]quinolin-11-yl)piperazin-1-yl]propan-1-ol.

Authors:  Gary S Nichol; Peda V L Boddupally; Biswanath De; Laurence H Hurley
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-11-30

10.  Identification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activity.

Authors:  Laura Guasch; Esther Sala; Miquel Mulero; Cristina Valls; Maria Josepa Salvadó; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.